Log In
BCIQ
Print this Print this
 

vipadenant (BIIB014) (formerly V2006)

Also known as: VR2006

  Manage Alerts
Collapse Summary General Information
Company Vernalis plc
DescriptionAdenosine A2A receptor antagonist
Molecular Target Adenosine A2A receptor (ADORA2A)
Mechanism of ActionAdenosine A2A receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerJuno Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$10.0M

$10.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2016

$10.0M

$10.0M

Undisclosed

10/09/2014

Undisclosed

0

Undisclosed

Get a free BioCentury trial today